# China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)

> **NCT05221580** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 887 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Ryzodeg®

## Key facts

- **NCT ID:** NCT05221580
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-18
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 887 (ACTUAL)
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05221580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05221580, "China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05221580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*